logo

Urogen Pharma Ltd. (URGN)



Trade URGN now with
  Date
  Headline
11/17/2020 8:04:17 AM UroGen Pharma Reports Final Topline Results From OPTIMA II Phase 2b Trial Evaluating Efficacy And Safety Of UGN-102
11/9/2020 8:15:57 AM UroGen Pharma Q3 Net Loss $28.8 Mln Or $1.31 Per Share
9/4/2020 8:07:46 AM UroGen Pharma Announces Grants Of Inducement Restricted Stock Units To Nineteen New Employees
8/27/2020 8:12:06 AM UroGen Pharma Says Phase 2 APOLLO Trial Did Not Meet Primary Endpoint
8/10/2020 8:13:51 AM UroGen Pharma Q2 Net Loss $31.3 Mln Or $1.44/Shr Vs Loss $22.5 Mln Or $1.08/Shr Last Year
4/3/2020 8:05:27 AM UroGen Announces Positive Interim Data From Phase 2b Study Of UGN-102 In Patients With LG IR-NMIBC
3/2/2020 8:11:38 AM UroGen Pharma Reports Q4 Net Loss Of $39.0 Mln Or $1.86/shr
12/19/2019 8:06:25 AM UroGen Announces FDA Filing Acceptance And Priority Review Of U.S. NDA For UGN-101
11/12/2019 8:11:57 AM UroGen Pharma Q3 Net Loss $22.3 Mln Vs. Net Loss $20.5 Mln Last Year
11/11/2019 8:05:23 AM UroGen Pharma Reaches License Agreement With Agenus Inc To Advance Treatment Of Urinary Tract Cancers
4/23/2019 8:08:13 AM UroGen Pharma Announces Early Stage Feasibility Agreement With Janssen
1/23/2019 10:18:42 PM UroGen Pharma Prices Public Offering Of 3.66 Mln Ordinary Shares At $41.00/shr
1/22/2019 4:01:38 PM UroGen Pharma Announces Proposed Public Offering Of Ordinary Shares
1/8/2019 8:10:19 AM UroGen Announces Results Of UGN-101 From Phase 3 OLYMPUS Trial For The Non-Surgical Treatment Of Patients With LG UTUC